全文获取类型
收费全文 | 9664篇 |
免费 | 495篇 |
国内免费 | 113篇 |
专业分类
耳鼻咽喉 | 129篇 |
儿科学 | 646篇 |
妇产科学 | 138篇 |
基础医学 | 840篇 |
口腔科学 | 194篇 |
临床医学 | 839篇 |
内科学 | 2619篇 |
皮肤病学 | 241篇 |
神经病学 | 502篇 |
特种医学 | 345篇 |
外科学 | 1278篇 |
综合类 | 240篇 |
预防医学 | 415篇 |
眼科学 | 331篇 |
药学 | 629篇 |
中国医学 | 15篇 |
肿瘤学 | 871篇 |
出版年
2023年 | 43篇 |
2021年 | 257篇 |
2020年 | 140篇 |
2019年 | 187篇 |
2018年 | 277篇 |
2017年 | 150篇 |
2016年 | 167篇 |
2015年 | 193篇 |
2014年 | 291篇 |
2013年 | 369篇 |
2012年 | 541篇 |
2011年 | 560篇 |
2010年 | 339篇 |
2009年 | 246篇 |
2008年 | 437篇 |
2007年 | 545篇 |
2006年 | 471篇 |
2005年 | 430篇 |
2004年 | 403篇 |
2003年 | 338篇 |
2002年 | 337篇 |
2001年 | 282篇 |
2000年 | 242篇 |
1999年 | 224篇 |
1998年 | 136篇 |
1997年 | 89篇 |
1996年 | 71篇 |
1995年 | 92篇 |
1994年 | 56篇 |
1993年 | 80篇 |
1992年 | 174篇 |
1991年 | 177篇 |
1990年 | 181篇 |
1989年 | 176篇 |
1988年 | 165篇 |
1987年 | 144篇 |
1986年 | 128篇 |
1985年 | 120篇 |
1984年 | 114篇 |
1983年 | 76篇 |
1982年 | 58篇 |
1981年 | 46篇 |
1980年 | 49篇 |
1979年 | 84篇 |
1978年 | 42篇 |
1977年 | 68篇 |
1974年 | 49篇 |
1972年 | 48篇 |
1970年 | 43篇 |
1969年 | 38篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Chi Andrew S. Tarapore Rohinton S. Hall Matthew D. Shonka Nicole Gardner Sharon Umemura Yoshie Sumrall Ashley Khatib Ziad Mueller Sabine Kline Cassie Zaky Wafik Khatua Soumen Weathers Shiao-Pei Odia Yazmin Niazi Toba N. Daghistani Doured Cherrick Irene Korones David Karajannis Matthias A. Kong Xiao-Tang Minturn Jane Waanders Angela Arillaga-Romany Isabel Batchelor Tracy Wen Patrick Y. Merdinger Krystal Schalop Lee Stogniew Martin Allen Joshua E. Oster Wolfgang Mehta Minesh P. 《Journal of neuro-oncology》2019,144(1):97-105
Journal of Neuro-Oncology - Smoking is agreed to be a major health risk factor, but it is debated whether it has an influence on perioperative adverse events (AEs) in elective cranial tumor... 相似文献
2.
Joseph H. Feinberg MD Priyesh Mehta DO Lawrence V. Gulotta MD Answorth A. Allen MD David W. Altchek MD Frank A. Cordasco MD Hollis G. Potter MD Russell F. Warren MD Thomas L. Wickiewicz MD Scott W. Wolfe MD 《Muscle & nerve》2019,59(2):247-249
Introduction: The purpose of this study was to determine whether surgical arthroscopic decompression or ultrasound-guided aspiration of a paralabral cyst would result in suprascapular nerve recovery from axonal regeneration based on electrodiagnostic testing. Methods: Nine patients with preoperative electromyography (EMG) evidence of suprascapular neuropathy due to paralabral cysts at the suprascapular or spinoglenoid notch were prospectively studied. Eight patients underwent arthroscopic surgical decompression, and 1 patient underwent ultrasound-guided aspiration. Postoperative EMG was performed in all patients to evaluate nerve regeneration. Results: Three (33%) patients had cysts at the suprascapular notch, whereas 6 (67%) patients had cysts at the spinoglenoid notch. All patients showed complete electrophysiological recovery after decompression. Discussion: Decompression of paralabral cysts at the suprascapular or spinoglenoid notch resulted in postoperative EMG evidence of nerve recovery. Long-term studies with a greater number of patients are required to elucidate time to recovery. Muscle Nerve 59 :247–249, 2019 相似文献
3.
Mahmoud B. Malas Jose Ignacio Leal Lorenzo Besma Nejim Todd M. Hanover Manish Mehta Vikram Kashyap Christopher J. Kwolek Richard Cambria 《Journal of vascular surgery》2019,69(6):1786-1796
ObjectiveWe report the 1-year outcomes of the Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure (ROADSTER) multicenter trial. This trial introduced a novel transcarotid neuroprotection system (NPS), the ENROUTE transcarotid NPS (Silk Road Medical Inc, Sunnyvale, Calif). Postoperative results demonstrated that the use of the ENROUTE transcarotid NPS is safe and effective. The aim of this study was to evaluate the safety of transcarotid artery revascularization (TCAR) and to present the 1-year outcomes.MethodsThis study is a prospective, single-arm clinical trial. Current enrollment occurs in 14 centers. Primary end points were incidence rates of ipsilateral stroke at 1 year after TCAR. Occurrence of stroke was ascertained by an independent Clinical Events Committee. Patients with anatomic or medical high-risk factors for carotid endarterectomy (CEA) were eligible to be enrolled in the ROADSTER trial.ResultsOverall, 165 patients were included in the long-term follow-up (112 of 141 patients from the pivotal phase and 53 of 78 patients from the extended access). Mean age was 73.9 years (range, 42.1-91.3 years). Patients aged 75 years and older were 43.3% of the cohort. The majority of patients were white (92.7%) and male (75.2%). Most patients were asymptomatic (79.9%). Anatomic risk factors were distributed as follows: contralateral carotid artery occlusion (11.0%), tandem stenosis of >70% (1.8%), high cervical carotid artery stenosis (25.0%), restenosis after CEA (25.6%), bilateral stenosis requiring treatment (4.3%), and hostile neck (14.6%). Medical high-risk criteria included two-vessel coronary artery disease (14.0%) and severe left ventricular dysfunction with ejection fraction <30% (1.8%). In general, 43.3% of patients had at least one anatomic high-risk factor, whereas 29.9% of patients had medical high-risk factors. Both subsets of factors were present simultaneously in 26.8% of the cohort. At 1-year follow-up, ipsilateral stroke incidence rate was 0.6%, and seven patients (4.2%) died. None of the deaths were neurologic in origin.ConclusionsTCAR with dynamic flow reversal had previously shown favorable 30-day perioperative outcomes. This excellent performance seems to extend to 1 year after TCAR as illustrated in this analysis. The promising results from the ROADSTER trial likely stem from the novel cerebral protection provided through the ENROUTE transcarotid NPS in comparison to distal embolic protection devices as well as the transcarotid approach's circumventing diseased aortic arch manipulation and minimizing embolization. TCAR offers a safe and durable revascularization option for patients who are deemed to be at high risk for CEA. 相似文献
4.
5.
6.
7.
The association between Gaucher disease (GD) and Parkinson disease (PD) has been described for almost two decades. In the biallelic state (homozygous or compound heterozygous) mutations in the glucocerebrosidase gene (GBA) may cause GD, in which glucosylceramide, the sphingolipid substrate of the glucocerebrosidase enzyme (GCase), accumulates in visceral organs leading to a number of clinical phenotypes. In the biallelic or heterozygous state, GBA mutations increase the risk for PD. Mutations of the GBA allele are the most significant genetic risk factor for idiopathic PD, found in 5%–20% of idiopathic PD cases depending on ethnicity. The neurological consequences of GBA mutations are reviewed and the proposition that GBA mutations result in a disparate but connected range of clinically and pathologically related neurological features is discussed. The literature relating to the clinical, biochemical and genetic basis of GBA PD, type 1 GD and neuronopathic GD is considered highlighting commonalities and distinctions between them. The evidence for a unifying disease mechanism is considered. 相似文献
8.
9.
10.